About This Fund
Scion Life Sciences has launched with an oversubscribed $310 million fund to create and build exceptional biotech companies. The New York City-based life sciences venture capital firm is dedicated to founding and building exceptional biotechnology companies that discover, develop, and seek to commercialize clinically transformational or curative new medicines. Scion is led by longstanding partners and experienced company-builders and investors, with a mission to create medicines that cure or transform the clinical management of serious and life-threatening diseases. The firm can make initial investments as small as a few thousand dollars in early-stage incubation efforts but is resourced to cumulatively deploy $60 million or more over the life of each portfolio company investment and to support promising portfolio companies from pre-seed stage through to IPO and beyond. The firm's investment strategy is based on three pillars: investing in therapeutic modalities and enabling technologies, therapeutic areas, diseases, and drug targets, and clinical problems that can be addressed with resources available to an independent biotechnology company. Scion has established an experienced team of scientific, medical, financial, technological, and operational leaders to actively found and build companies. The team has begun investing its fund with four promising company formation efforts underway. Additionally, Scion Innovations has been established to provide in-house R&D capabilities and operational resources to make efficient, objective decisions about portfolio company investments. The firm's proactive and data-driven approach to company building enables it to generate a concentrated portfolio of best ideas optimized to yield real medicines that change the lives of patients and caregivers. Scion's target investments include clinically important new medicines, with a long-term focus on building sustainably operating biotechnology companies capable of ascending to valuations in the tens of billions as they commercialize clinically transformational new medicines. The fund's investment strategy is supported by historical industry data and sustained, long-term support, enabling it to build companies capable of generating solutions to clinically important problems. Overall, Scion Life Sciences is committed to meaningfully improving human health through long-term ownership of clinically transformative therapies, supporting impactful and sustainable advancements with a strategic and pragmatic approach to investment and innovation.